SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant in South Africa and are rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed. Notably, the susceptibility of the 501Y.V2 variants to 12 of 17 neutralizing monoclonal antibodies was substantially diminished, and the neutralization ability of the sera from convalescent patients and immunized mice was also reduced for these variants. The neutralization resistance was mainly caused by E484K and N501Y mutations in the receptor-binding domain of spike. The enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of spillover of the 501Y.V2 variants to mice. Moreover, the neutralization resistance we detected for the 501Y.V2 variants suggests the potential for compromised efficacy of monoclonal antibodies and vaccines.
| Errataetall: |
CommentIn: Signal Transduct Target Ther. 2021 Jul 27;6(1):284. - PMID 34315847 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:184 |
|---|---|
| Enthalten in: |
Cell - 184(2021), 9 vom: 29. Apr., Seite 2362-2371.e9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Qianqian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.05.2021 Date Revised 11.02.2024 published: Print-Electronic CommentIn: Signal Transduct Target Ther. 2021 Jul 27;6(1):284. - PMID 34315847 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cell.2021.02.042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322921163 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322921163 | ||
| 003 | DE-627 | ||
| 005 | 20240211231843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cell.2021.02.042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM322921163 | ||
| 035 | |a (NLM)33735608 | ||
| 035 | |a (PII)S0092-8674(21)00231-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Qianqian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.05.2021 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Signal Transduct Target Ther. 2021 Jul 27;6(1):284. - PMID 34315847 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant in South Africa and are rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed. Notably, the susceptibility of the 501Y.V2 variants to 12 of 17 neutralizing monoclonal antibodies was substantially diminished, and the neutralization ability of the sera from convalescent patients and immunized mice was also reduced for these variants. The neutralization resistance was mainly caused by E484K and N501Y mutations in the receptor-binding domain of spike. The enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of spillover of the 501Y.V2 variants to mice. Moreover, the neutralization resistance we detected for the 501Y.V2 variants suggests the potential for compromised efficacy of monoclonal antibodies and vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 501Y.V2 | |
| 650 | 4 | |a E484K | |
| 650 | 4 | |a K417N | |
| 650 | 4 | |a N501Y | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a immune escape | |
| 650 | 4 | |a infectivity | |
| 650 | 4 | |a mutation | |
| 650 | 4 | |a neutralizing antibody | |
| 650 | 4 | |a receptor binding region | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Nie, Jianhui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jiajing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Ruxia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Haixin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shuo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mengyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Chenyan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Nie, Lingling |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Haiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Junkai |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Haoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yuelei |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Liangzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Linqi |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Xiaowang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wenbo |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Youchun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell |d 1974 |g 184(2021), 9 vom: 29. Apr., Seite 2362-2371.e9 |w (DE-627)NLM000088935 |x 1097-4172 |7 nnns |
| 773 | 1 | 8 | |g volume:184 |g year:2021 |g number:9 |g day:29 |g month:04 |g pages:2362-2371.e9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cell.2021.02.042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 184 |j 2021 |e 9 |b 29 |c 04 |h 2362-2371.e9 | ||